Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$20.19 +1.3%	$21.11	$19.00 ▼ $26.58	$2.44B	0.7	1.50 million shs	1.14 million shs
KALV KalVista Pharmaceuticals	$13.59 +3.3%	$13.45	$7.30 ▼ $16.32	$662.47M	0.05	703,043 shs	342,039 shs
KNSA Kiniksa Pharmaceuticals International	$33.70 +0.4%	$30.10	$17.82 ▼ $34.55	$2.49B	0.14	617,738 shs	352,386 shs
RXRX Recursion Pharmaceuticals	$4.89 +1.2%	$5.45	$3.79 ▼ $12.36	$2.10B	0.93	18.66 million shs	11.41 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	-3.30%	-1.53%	-4.91%	-18.74%	-2.97%
KALV KalVista Pharmaceuticals	+1.31%	+2.73%	-9.74%	+15.44%	+0.77%
KNSA Kiniksa Pharmaceuticals International	+1.60%	+1.27%	+27.50%	+23.15%	+21.85%
RXRX Recursion Pharmaceuticals	0.00%	-5.11%	-25.58%	+10.02%	-38.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.8913 of 5 stars	3.6	1.0	3.9	3.4	3.3	3.8
KALV KalVista Pharmaceuticals	3.7866 of 5 stars	3.6	1.0	4.4	2.5	0.8	0.6
KNSA Kiniksa Pharmaceuticals International	2.411 of 5 stars	2.5	3.0	0.0	2.7	3.3	0.6
RXRX Recursion Pharmaceuticals	2.2931 of 5 stars	3.2	1.0	0.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.13	Buy	$33.20	64.58% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	93.21% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$41.17	22.23% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	43.00% Upside

Current Analyst Ratings Breakdown

Latest KALV, RXRX, CPRX, and KNSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	CPRX Catalyst Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $54.00
7/21/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$491.73M	5.02	$2.39 per share	8.43	$6.99 per share	2.89
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
KNSA Kiniksa Pharmaceuticals International	$423.24M	5.90	N/A	N/A	$6.68 per share	5.04
RXRX Recursion Pharmaceuticals	$58.84M	36.12	N/A	N/A	$2.12 per share	2.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$163.89M	$1.65	12.23	9.47	0.84	37.36%	40.78%	35.36%	11/5/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	$0.04	842.24	134.72	N/A	0.90%	1.05%	0.80%	11/4/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.78	N/A	N/A	N/A	-1,004.91%	-76.09%	-54.29%	11/5/2025 (Estimated)

Latest KALV, RXRX, CPRX, and KNSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2025	Q1 2026	KALV KalVista Pharmaceuticals	-$0.91	N/A	N/A	N/A	$1.97 million	N/A
8/5/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.35	-$0.41	-$0.06	-$0.41	$15.38 million	$19.10 million
7/29/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.18	$0.23	+$0.05	$0.23	$145.21 million	$156.80 million
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	6.71	6.55
KALV KalVista Pharmaceuticals	N/A	5.35	5.35
KNSA Kiniksa Pharmaceuticals International	N/A	3.57	3.16
RXRX Recursion Pharmaceuticals	0.02	3.58	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
KALV KalVista Pharmaceuticals	N/A
KNSA Kiniksa Pharmaceuticals International	53.95%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
KALV KalVista Pharmaceuticals	4.30%
KNSA Kiniksa Pharmaceuticals International	53.48%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	122.39 million	109.66 million	Optionable
KALV KalVista Pharmaceuticals	100	50.34 million	48.18 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	74.11 million	34.48 million	Optionable
RXRX Recursion Pharmaceuticals	400	434.15 million	397.55 million	Optionable

KALV, RXRX, CPRX, and KNSA Headlines

Recent News About These Companies

Recursion to Participate in Upcoming Investor Conferences

August 27 at 8:00 AM | globenewswire.com

Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) and Organogenesis (NASDAQ:ORGO)

August 27 at 2:29 AM | americanbankingnews.com

1,912,620 Shares in Recursion Pharmaceuticals, Inc. $RXRX Purchased by Nuveen LLC

August 25 at 3:41 AM | marketbeat.com

Needham Maintains Buy Rating on Recursion (RXRX)

August 24 at 3:29 AM | msn.com

The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode

August 23, 2025 | fool.com

Recursion Pharmaceuticals, Inc. $RXRX Stock Position Reduced by Vanguard Group Inc.

August 23, 2025 | marketbeat.com

Why Recursion Pharmaceuticals Stock Caught a Cold This Week

August 22, 2025 | fool.com

Recursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025

August 22, 2025 | finance.yahoo.com

Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Sells 36,599 Shares of Stock

August 21, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares

August 21, 2025 | insidermonkey.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% - Here's Why

August 20, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 36,599 Shares

August 20, 2025 | insidertrades.com

EverSource Wealth Advisors LLC Raises Stake in Recursion Pharmaceuticals, Inc. $RXRX

August 20, 2025 | marketbeat.com

LPL Financial LLC Purchases 57,305 Shares of Recursion Pharmaceuticals, Inc. $RXRX

August 20, 2025 | marketbeat.com

Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data

August 19, 2025 | seekingalpha.com

Liontrust Investment Partners LLP Lowers Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

August 18, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Vestmark Advisory Solutions Inc.

August 18, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

August 17, 2025 | insidermonkey.com

Analysts Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) PT at $7.00

August 16, 2025 | americanbankingnews.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Brokerages

August 14, 2025 | marketbeat.com

Recursion Pharmaceuticals: Two Clinical Readouts In H2'25

August 13, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV, RXRX, CPRX, and KNSA Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$20.19 +0.25 (+1.25%)

Closing price 04:00 PM Eastern

Extended Trading

$20.23 +0.04 (+0.18%)

As of 07:56 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

KalVista Pharmaceuticals NASDAQ:KALV

$13.59 +0.43 (+3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$13.65 +0.06 (+0.43%)

As of 07:28 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$33.70 +0.13 (+0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$33.99 +0.29 (+0.86%)

As of 05:05 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Recursion Pharmaceuticals NASDAQ:RXRX

$4.89 +0.06 (+1.24%)

Closing price 04:00 PM Eastern

Extended Trading

$4.88 -0.01 (-0.20%)

As of 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time